Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by AgeX Therapeutics, Inc. (trading symbol: AGE) on December 28, 2020. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (November 23, 2020), there were 37,689,003 shares of common stock outstanding. A total of 29,150,269 shares (77.34% of voting power) were represented at the meeting. Stockholders approved the following matters:
- Election of Directors: Four directors were elected to serve until the next annual meeting. Michael D. West received the highest number of votes for (23,320,554), while Gregory H. Bailey received the lowest (19,783,462). There were 5,376,549 broker non-votes on this matter.
- Ratification of Accountants: The appointment of OUM & Co. LLP as independent registered public accountants for the 2020 fiscal year was ratified with 28,922,561 votes for, 138,712 against, and 88,996 abstentions.
- Juvenescence Proposal: Stockholders approved a proposal permitting Juvenescence Limited to acquire additional shares of AgeX common stock via warrant exercise or loan conversion, even if this results in Juvenescence owning more than 19.9% of outstanding stock at a price below market/book value or owning 50% or more of outstanding shares. The vote was 20,131,315 for, 3,549,370 against, and 93,035 abstentions.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the implications of the approved Juvenescence Proposal regarding potential changes in ownership structure and share dilution.
Key Facts for Investor Verification
- Verify the current ownership percentage of Juvenescence Limited and the terms of the warrants or loans referenced in the approved proposal.
- Confirm the impact of the Juvenescence Proposal on potential future dilution of existing shareholders.
- Review the full 2020 Annual Report (Form 10-K) for financial performance data, as this 8-K contains no financial metrics.
- Note the significant number of broker non-votes (5,376,549) on the director election and Juvenescence Proposal, indicating a portion of shares held in street name did not receive voting instructions.